Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
about
Osteoimmunology: interactions of the bone and immune systemThymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosisCXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cellsTreatment of multiple myeloma bone disease: experimental and clinical data.Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.Advances in the understanding of myeloma bone disease and tumour growth.Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas.The effects of proteasome inhibitors on bone remodeling in multiple myeloma.Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.Bone disease in multiple myeloma: pathophysiology and management.Inhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo.In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.Myelomagenesis: capturing early microenvironment changesCXCL12-γ in primary tumors drives breast cancer metastasis.Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblastsIn vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaTug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.Novel Bruton's tyrosine kinase inhibitors currently in development.Multiple myeloma in the marrow: pathogenesis and treatments.The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.The pathogenesis of the bone disease of multiple myeloma.Cytoplasmic trapping of CXCR4 in hepatocellular carcinoma cell lines.Osteoimmunology: cytokines and the skeletal system.Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.Defects in osteoblast function but no changes in long-term repopulating potential of hematopoietic stem cells in a mouse chronic inflammatory arthritis model.[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values.Aseptic necrosis at multiple localisations in a lupus patient with lymphoma.Environmental Factors Impacting Bone-Relevant Chemokines.Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone diseaseTumor-host cell interactions in the bone disease of myeloma.Pathogenesis and management of myeloma bone disease.Hematopoietic stem cell homing to injured tissues.Biological aspects of angiogenesis in multiple myeloma.Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.
P2860
Q24655113-659B1D94-68BA-406C-AF4A-DE4D7E1A9300Q28476755-859BE461-98D9-4099-A096-D97A8515C993Q30480094-B9EB2CF8-94A8-46E6-ACFC-B5C3DB4DD2AEQ30868833-8361DB98-6EAD-4241-A680-8FEC67B8BBC6Q33558170-C2F0AC1D-6FF2-40B4-A863-323BDF078E56Q33829022-62EAEC2E-B0B5-44B6-A082-043FB43EA62FQ33829094-846EFC2C-2C3B-4727-A26B-ED719C49A830Q33883005-E56373D2-64BD-46BD-9239-E5923C8CD49FQ33918020-57687D14-59A4-485A-9FF2-B1531E6B405DQ33953955-3D5A7E5A-4DAA-4519-8734-0153F8BA0950Q34045789-12745D05-2AEE-4C11-ACD0-A34B17D33814Q34450321-AA928F8D-9E27-4E69-BE2E-44B9EEFD1FF6Q34501627-3C6647B2-DB62-42CB-8302-91B41DF45A13Q34519296-9DD3C2D4-F227-4E9C-B30E-18CEE24FCB7BQ34664016-E9179C40-A699-47D1-969E-172D80956EB5Q34956540-B937DCB2-D930-4065-A895-F2518DABD3E9Q35144762-8B0B8658-6C1E-4DB7-BFDF-0162CEE203F0Q35483867-66228BE1-D8D9-4C7F-8BE8-9B93AFB2AF9CQ36206430-5B6394F2-D7A4-44A6-A6BD-978C6EA95715Q36289608-E66E35FB-2EA7-47F6-8CBD-50915962ECBDQ36318564-ADEAA159-D264-41E2-9F71-4978880619B4Q36367811-5AE2619F-F561-4334-BF83-68F76BCE5A17Q36593549-8F4E9ADE-834D-4B3A-8737-D0762BACA452Q36673755-1A0AF976-AC3E-4AD2-B640-2B7ED18A473DQ36725401-A8E57B04-B146-4790-93CC-A2DB2CBAFDB2Q36870585-8B5A3E03-6698-4B1C-8037-09AF42D4A3D0Q37136324-AEBA62DB-26CD-40F8-8F58-149546863E3BQ37230169-4C202D1D-7461-410B-B5C6-3340D8B1914DQ37235713-C56FF97A-73C0-4B91-AEFA-8FF800E84BDEQ37352728-D6BC3E20-6565-456C-9EC4-0BC9660BCCD6Q37420508-852436FD-D2DC-4672-857D-BC2F37D1DE6DQ37541868-6D051D3D-3D69-434A-85E8-6D7ECCD52459Q37638876-C5ED00BD-E919-418E-8A0C-6EEB74118853Q37639340-0ED3E305-D1C9-440D-A60D-7FE0B11E2885Q37678085-AEED208A-9C7E-4A83-9106-9DBF7E2444B6Q37771082-CD449CD6-29FF-4EC3-87F8-8371B61029B0Q37810077-23AB4FEE-C117-4F8C-89AA-64E7A86AF3C2Q37845721-A83CAA01-39D7-48A4-A50D-D36A8AB47421Q37956524-75C816AA-E971-47A8-942C-A7CC50FDAE98Q38073136-0724B229-1584-4E22-81F5-36E2551FC542
P2860
Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Elevated serum levels of strom ...... in multiple myeloma patients.
@en
type
label
Elevated serum levels of strom ...... in multiple myeloma patients.
@en
prefLabel
Elevated serum levels of strom ...... in multiple myeloma patients.
@en
P2093
P50
P1433
P1476
Elevated serum levels of strom ...... e in multiple myeloma patients
@en
P2093
Amanda N Farrugia
Angela Kortesidis
Jim Manavis
Nobutaka Fujii
Peter Diamond
Tsvee Lapidot
P304
P356
10.1158/0008-5472.CAN-04-1687
P407
P577
2005-03-01T00:00:00Z